Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7717828 | 0.82 | TSHR (0.39) | PNMTIDO1TSHR | |
| SCHEMBL8525795 | 0.77 | IDO1 (0.52) | PNMTIDO1TSHRTAAR1SLC6A2 | |
| SCHEMBL29652122 | 0.75 | FDPS (0.50) | PNMTTSHRTAAR1SLC6A2SLC6A4 | |
| SCHEMBL28443237 | 0.75 | TAAR1 (0.46) | TSHRTAAR1 | |
| SCHEMBL7631074 | 0.75 | HSPA5 (0.54) | HSPA5IDO1TSHRTAAR1 | |
| SCHEMBL9718549 | 0.74 | RIPK1 (0.50) | HSPA5HTR2ATAAR1SLC6A2SLC6A4 | |
| SCHEMBL9352728 | 0.72 | IDO1 (0.52) | IDO1SLC6A2SLC6A4 | |
| SCHEMBL17224808 | 0.72 | CYP1A2 (0.52) | TSHR | |
| Chlorobenzene SCHEMBL27309368 | 0.70 | TSHR (0.46) | PNMTIDO1TSHRTAAR1SLC6A2 | |
| SCHEMBL8550582 | 0.69 | HSPA5 (0.46) | HSPA5HTR2APNMTIDO1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | HSPA5 3807/4885HTR2A 1893/4885PNMT 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.